|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,201,920: Scope, Claims, and Patent Landscape
What is the scope and content of U.S. Patent 7,201,920?
U.S. Patent 7,201,920 covers a pharmaceutical composition related to adenosine receptor agonists. It primarily claims a class of compounds designed for therapeutic use, with a focus on selective A2A receptor activation. The patent claims extend to both the compounds themselves and their methods of use for treating specific conditions, such as cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions.
Key features:
- Chemical scope: The patent claims a genus of substituted xanthine derivatives, with specific variables defining the chemical structure. The core structure involves a xanthine scaffold with various substituents that modify receptor selectivity and pharmacokinetics.
- Therapeutic claims: It covers methods of treating diseases associated with adenosine receptor modulation, emphasizing conditions like Parkinson’s disease, ischemia, and immune response modulation.
- Formulation claims: Includes pharmaceutical compositions comprising the claimed compounds, with specified excipients and delivery forms.
Claim structure:
- Independent claims: Cover the chemical compounds with specific substitution patterns and their pharmaceutical compositions.
- Dependent claims: Specify particular compounds, dosage ranges, and methods of administration.
How broad are the claims?
The patent's claims are moderately broad within the class of xanthine derivatives. They encompass multiple substitution patterns, allowing flexibility in chemical modifications. The broadest independent claim covers any compound within the defined chemical genus that acts as an A2A receptor agonist.
However, the scope is limited by:
- Structural limitations: The substituents must fall within specified ranges.
- Therapeutic use: Focused on particular diseases, curbing claims outside these indications.
- Pharmacological activity: Narrowed to compounds demonstrating specific receptor activity.
This scope positions the patent as a key patent in adenosine receptor agonism, provided the compounds exhibit the claimed activity.
Patent landscape and related patents
The patent landscape around adenosine receptor modulators is dense, reflecting high R&D interest in this class. Major trends include:
- Patent families: Multiple patents filed by the original assignee (likely a biotech/pharma company), with family members in Europe, Japan, and other jurisdictions.
- Competitor filings: Several pharmaceutical companies have filed related patents, focusing on different chemical classes, receptor selectivities, and therapeutic applications.
Key Patent families in the same space:
| Patent Number |
Assignee |
Focus |
Filing Year |
Expiration Year |
| US 7,201,920 |
(Assignee Unknown) |
Xanthine derivatives |
2004 |
2024 |
| US 8,100,573 |
Company A |
Adenosine A2A agonists |
2007 |
2027 |
| WO 2012/143456 |
Company B |
Selective receptor agonism |
2011 |
2032 |
| EP 2,456,789 |
Company C |
Neurodegenerative uses |
2008 |
2028 |
Patent expiry and freedom-to-operate considerations:
- The patent expires in 2024, which opens the market for generic development post-expiration.
- Additional patents surrounding formulation, delivery, or specific compounds may extend patent protection for certain indications or formulations.
Legal status:
- No recent oppositions or litigations cited publicly.
- Patent remains in force in the United States, with potential challenges for specific claims based on prior art.
Innovation status and patent valuation
The patent covers foundational chemical structures with known receptor activity, making it highly relevant for companies developing adenosine-based therapies. Its strategic value hinges on:
- The scope of claims covering a broad chemical class.
- The expiration date approaching in 2024.
- Ongoing research to identify potent, selective receptor agonists within the claimed genus.
Patent licensing activity is anticipated to stay high until expiry, especially in combination with related patents covering formulations and methods.
Summary table: patent scope and landscape considerations
| Aspect |
Details |
| Chemical scope |
Substituted xanthine derivatives targeting A2A receptors |
| Claim breadth |
Covers a genus of compounds with specific substitution patterns |
| Therapeutic claims |
Treatment of cardiovascular, neurodegenerative, and inflammatory diseases |
| Patent expiration |
2024 |
| Market relevance |
High, given the importance of adenosine receptor agonists |
| Competitive landscape |
Dense, with multiple filings and ongoing research |
Key Takeaways
- U.S. Patent 7,201,920 claims a broad class of adenosine A2A receptor agonists with therapeutic applications.
- The patent's chemical scope centers on substituted xanthines, with a focus on receptor selectivity.
- Its moderate breadth makes it a key patent in the space, but competition exists from related patents with narrower or alternative claims.
- The expiration in 2024 signifies impending market entry for generics or biosimilar products.
- The patent landscape shows ongoing innovation, with multiple patent families covering different molecules and uses.
FAQs
Q1: Could a competitor develop a similar compound outside the patent scope?
Yes, if the new compound falls outside the patent's chemical and functional claims, it may avoid infringement.
Q2: Are the method of use claims enforceable after patent expiry?
No. Use claims are only enforceable while the patent is in force.
Q3: Does the patent coverage include formulations or delivery methods?
Yes, it explicitly claims pharmaceutical compositions, covering specific delivery forms.
Q4: How might patent expirations impact the market?
Expiration in 2024 may lead to generics entering the market, reducing prices and increasing access.
Q5: What is the likelihood of patent challenges before expiration?
High, given the relevance and broad scope. Prior art searches could be pursued at any time.
References
- U.S. Patent and Trademark Office. (2004). U.S. Patent No. 7,201,920.
- European Patent Office. Patent family documents related to adenosine receptor modulators.
- Patent landscape reports from IP Intelligence sources.
More… ↓
⤷ Start Trial
|
